Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, and Catalent Biologics’ Paragon Gene Therapy unit, the leading viral vector development and manufacturing partner for gene therapies, today announced an arrangement under which Paragon Gene Therapy will assume the leases to two Novavax product development and manufacturing facilities, giving it immediate access to state-of-the-art manufacturing equipment, people and space to accelerate the growth of its gene therapy development and manufacturing business.
{iframe}https://www.globenewswire.com/news-release/2019/06/27/1875091/0/en/Novavax-and-Catalent-Biologics-Enter-Strategic-Partnership-Allowing-Catalent-Biologics-to-Expand-Gene-Therapy-Footprint-with-Acquisition-of-Novavax-Manufacturing-Assets-and-Capabil.html{/iframe}